Mitochondrial microRNAs Are Dysregulated in Patients with Fabry Disease.

J Pharmacol Exp Ther

Department of Advanced Biomedical Sciences (J.G., A.F., D.S., F.C., A.B., R.A., G.I.); Interdepartmental Center of Research on Hypertension and Related Conditions (J.G., G.I.), and Department of Public Health (A.P., E.R.); Federico II University, Naples, Italy; and Departments of Medicine (Cardiology) and Molecular Pharmacology, Wilf Family Cardiovascular Research Institute, Institute for Neuroimmunology and Inflammation, Fleischer Institute for Diabetes and Metabolism, Einstein Institute for Aging Research, Einstein-Sinai Diabetes Research Center, Albert Einstein College of Medicine, New York City, New York (J.G., F.V., G.S.)

Published: January 2023

AI Article Synopsis

  • Fabry disease is a rare condition caused by a problem in a gene that leads to the build-up of a substance called GB3 in the body, affecting various organs.* -
  • Researchers found that changes in tiny RNA molecules related to mitochondria (the cell's powerhouses) are linked to the disease, suggesting that these molecules could help monitor the disease or even explain some of its symptoms.* -
  • This study is important because it shows that these mitochondrial RNA molecules (called mitomiRs) could be new tools for understanding and possibly treating Fabry disease better.*

Article Abstract

Fabry disease (FD) is a lysosomal storage disorder caused by mutations in the gene for -galactosidase A, inducing a progressive accumulation of globotriaosylceramide (GB3) and its metabolites in different organs and tissues. GB3 deposition does not fully explain the clinical manifestations of FD, and other pathogenetic mechanisms have been proposed, requiring the identification of new biomarkers for monitoring FD patients. Emerging evidence suggests the involvement of mitochondrial alterations in FD. Here, we propose mitochondrial-related microRNAs (miRs) as potential biomarkers of mitochondrial involvement in FD. Indeed, we demonstate that miRs regulating different aspects of mitochondrial homeostasis including expression and assembly of respiratory chain, mitogenesis, antioxidant capacity, and apoptosis are consistently dysregulated in FD patients. Our data unveil a novel noncoding RNA signature of FD patients, indicating mitochondrial-related miRs as new potential pathogenic players and biomarkers in FD. SIGNIFICANCE STATEMENT: This study demonstrates for the first time that a specific signature of circulating mitochondrial miRs (mitomiRs) is dysregulated in FD patients. MitomiRs regulating fundamental aspects of mitochondrial homeostasis and fitness, including expression and assembly of the respiratory chain, mitogenesis, antioxidant capacity, and apoptosis are significantly dysregulated in FD patients. Taken together, these new findings introduce mitomiRs as unprecedented biomarkers of FD and point at mitochondrial dysfunction as a novel potential mechanistic target for therapeutic approaches.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9827504PMC
http://dx.doi.org/10.1124/jpet.122.001250DOI Listing

Publication Analysis

Top Keywords

dysregulated patients
16
fabry disease
8
mirs potential
8
aspects mitochondrial
8
mitochondrial homeostasis
8
including expression
8
expression assembly
8
assembly respiratory
8
respiratory chain
8
chain mitogenesis
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!